A decisive advantage of an MCT4 isoform-specific inhibitor for ccRCC therapeutic use would be the highly restricted expression in normal body tissues in comparison to the ubiquitously expressed MCT1 11. This evidence concerns the gene SLC16A1 and nonpapillary renal cell carcinoma.